News

Translational Research In Oncology (TRIO) Appoints Board Member

Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced the appointment of Prof. Seock-Ah Im to the Company’s Board of Directors, effective March 15, 2021. Based…

TRIO Continues Support for ACRP Partners in Workforce Advancement

The Association of Clinical Research Professionals (ACRP) is pleased to announce the continued support of TRIO (Translational Research in Oncology) as a Workforce Champion member of the Partners in Workforce…

TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial

Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast…

TRIO Partners with eClinical Solutions to Power Digital Transformation in Clinical Trials for Cancer

MANSFIELD, MASS. (PRWEB) APRIL 15, 2021 eClinical Solutions LLC, a global provider of cloud-based enterprise software and software-driven clinical data services that accelerate digital clinical initiatives, today announced that Translational Research in…

Translational Research in Oncology (TRIO) Named Top Alberta Employer for Second Year

Translational Research in Oncology (TRIO), a global academic clinical research organization, is pleased to be recognized as one of Alberta’s Top 70 Employers, an editorial competition that recognizes Alberta’s best…

Translational Research in Oncology (TRIO) Enrolls First Patient in Early Breast Cancer Phase 2 Trial

Translational Research in Oncology (TRIO), a global academic clinical research organization, announced today enrolment of the first patient in a Phase 2 randomized, multi-center, open-label clinical trial of GDC-9545 sponsored…

Translational Research In Oncology (TRIO) Appoints Industry And Clinical Experts To Board Of Directors

Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced the appointment of two new members to the Company’s Board of Directors, effective February 1, 2020. Joining…

Translational Research In Oncology (TRIO) Initiates Phase I Study For MT-5111

Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced enrollment of the first patient in a Phase I study with its partner Molecular Templates (Nasdaq: MTEM).…

TRIO Partners With Molecular Templates For First-In-Human Phase I Study For MT-5111

Translational Research in Oncology (TRIO), a global academic clinical research organization, today announced it has partnered with Molecular Templates (Nasdaq: MTEM) to conduct its First-in-Human study for patients with previously…

TRIO Enrolls First Patient Into PHASE III NATALEE Clinical Trial

– Timely Enrolment Signifies Milestone in TRIO – EDMONTON, Alberta (January 14, 2019) – Translational Research In Oncology (TRIO), in collaboration with Novartis and under the direction of Dennis Slamon,…